MediWound Ltd. (MDWD) director discloses shares, RSUs and options stake

Rhea-AI Filing Summary

MediWound Ltd. director David Morton Fox filed an initial statement of beneficial ownership, outlining his equity stake in the company. He directly holds ordinary shares and additional ordinary shares underlying restricted stock units that were granted on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

Fox also reports a series of equity incentives. These include Series A warrants$13.4750 per share, expiring on November 28, 2026. He holds multiple stock option grants, such as options over 14,285 ordinary shares at $12.2500 per share expiring on June 29, 2030, and other tranches with exercise prices between $11.8850 and $37.5200 expiring from 2031 through 2036. This filing records existing holdings and does not show new market transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fox David Morton

(Last) (First) (Middle)

C/O MEDIWOUND LTD.

42 HAYARKON STREET

(Street)

YAVNE 8122745

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MediWound Ltd. [ MDWD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	18,746	D
Ordinary shares(1)	750	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Warrants	11/28/2022	11/28/2026	Ordinary shares	6,534	$13.475	D
Stock Option (right to buy ordinary shares)	06/29/2021	06/29/2030	Ordinary shares	14,285	$12.25	D
Stock Option (right to buy ordinary shares)	06/15/2022	06/15/2031	Ordinary shares	1,607	$37.52	D
Stock Option (right to buy ordinary shares)	05/16/2023	05/16/2032	Ordinary shares	5,357	$14.42	D
Stock Option (right to buy ordinary shares)	05/31/2024	05/30/2033	Ordinary shares	5,900	$11.885	D
Stock Option (right to buy ordinary shares)	02/26/2025	02/26/2034	Ordinary shares	7,542	$12.729	D
Stock Option (right to buy ordinary shares)	02/11/2026	02/11/2035	Ordinary shares	5,600	$18.54	D
Stock Option (right to buy ordinary shares)	(2)	03/04/2036	Ordinary shares	6,250	$17.6	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

2. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

	/s/ Yaron Meyer, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the MediWound Ltd. (MDWD) Form 3 filing show for director David Morton Fox?

The Form 3 shows director David Morton Fox’s initial equity holdings in MediWound. It lists his direct ordinary share position, restricted stock units granted on March 4, 2026, and multiple stock option and warrant positions over ordinary shares with various exercise prices and expirations.

How many MediWound (MDWD) ordinary shares are covered by David Morton Fox’s Series A warrants and key options?

Fox’s Series A warrants cover 6,534 ordinary shares at an exercise price of $13.4750. One key stock option grant covers 14,285 ordinary shares at $12.2500 per share, with additional option tranches over smaller ordinary share amounts at other exercise prices.

What are the main exercise prices and expirations of David Morton Fox’s MediWound (MDWD) derivative awards?

The filing shows a Series A warrant exercisable at $13.4750 expiring November 28, 2026. Stock options have exercise prices between $11.8850 and $37.5200, with expiration dates ranging from June 29, 2030 through March 4, 2036, providing long-dated exposure to MediWound shares.

Does the MediWound (MDWD) Form 3 for David Morton Fox report any stock purchases or sales?

The Form 3 does not report stock purchases or sales. It functions as an initial ownership snapshot, listing Fox’s existing ordinary share holdings, restricted stock units, and outstanding Series A warrants and stock options without indicating new market transactions in MediWound securities.

How are restricted stock units described in David Morton Fox’s MediWound (MDWD) Form 3?

The filing notes that certain ordinary shares reported consist of shares underlying restricted stock units granted on March 4, 2026. These RSUs are structured to vest 100% on the one-year anniversary of the grant date, reflecting time-based vesting rather than immediate share ownership.

What does MediWound (MDWD) investors learn from the derivativeSummary in David Morton Fox’s Form 3?

The derivativeSummary shows Fox’s remaining unexercised Series A warrants and stock options over MediWound ordinary shares. It details each award’s exercise price, expiration date, and underlying share count, clarifying the scale and timing of his potential future share acquisitions through equity incentives.